Bromantane | |
---|---|
Нашим русским друзьям | |
Chemical Nomenclature | |
Common names | Bromantane, Bromantan, Ladasten |
Substitutive name | Bromantane |
Systematic name | N-(4-Bromophenyl)adamantan-2-amine |
Class Membership | |
Psychoactive class | Stimulant / Nootropic |
Chemical class | Adamantane |
Bromantane (Ladasten) is a “actoprotector”: Actoprotectors improve body stability against physical stresses without raising oxygen consumption or heat. Actoprotectors are metabolic molecules with antihypoxic properties. They vary from antihypoxants by directly stimulating protein synthesis and working capability. Similar to stimulants, yet different: Actoprotectors are non-exhaustive. Actoprotectors boost not only cerebral (intellectual) but also physical work capacity, unlike nootropics.
LiteratureReichlin, S. (1969). Handbook of Experimental Pharmacology. The American Journal of The Medical Sciences (Vol. 258). https://doi.org/10.1097/00000441-196911000-00008Krapivin, S. V, Sergeeva, S. A., & Morozov, I. S. (1993). [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]. Biulleten’ Eksperimental’noi Biologii I Meditsiny, 116(11), 515–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8312546Burnat, P., Payen, A., Brumant-Payen, C. Le, Hugon, M., & Ceppa, F. (1997). Bromontan, a new doping agent. The Lancet, 350(9082), 963–964. https://doi.org/10.1016/S0140-6736(05)63310-7Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., & Zhirnov, E. N. (2000). [The neuro- and psychophysiological effects of bromantane]. Voenno-Meditsinskii Zhurnal, 321(8), 61–5, 96. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10998997Iezhitsa, I. N., Spasov, A. A., & Bugaeva, L. I. (2001). Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicology and Teratology, 23(2), 213–222. https://doi.org/10.1016/S0892-0362(01)00119-2Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., & Morozov, I. S. (2002). Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bulletin of Experimental Biology and Medicine, 133(4), 380–383. https://doi.org/10.1023/A:1016206306875Oliynyk, S., & Oh, S. (2012). The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance. Biomolecules and Therapeutics, 20(5), 446–456. https://doi.org/10.4062/biomolther.2012.20.5.446Morozov, I. S., Klimova, N. V, Karpova, T. D., & Shestopalov, S. S. (n.d.). [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]. Eksperimental’naia I Klinicheskaia Farmakologiia, 62(2), 3–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10340117Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V, & Gaĭnetdinov, R. R. (n.d.). [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. Eksperimental’naia I Klinicheskaia Farmakologiia, 58(4), 8–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/758076
References
- ↑ Oliynyk, S., Oh, S. (September 2012). “The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance”. Biomolecules & Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. ISSN 1976-9148.
- ↑ Krapivin, S. V., Sergeeva, S. A., Morozov, I. S. (November 1993). “[A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]”. Biulleten’ Eksperimental’noi Biologii I Meditsiny. 116 (11): 515–518. ISSN 0365-9615.
- ↑ Burnat, P., Payen, A., Brumant-Payen, C. L., Hugon, M., Ceppa, F. (September 1997). “Bromontan, a new doping agent”. The Lancet. 350 (9082): 963–964. doi:10.1016/S0140-6736(05)63310-7. ISSN 0140-6736.
- ↑ Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., Zhirnov, E. N. (August 2000). “[The neuro- and psychophysiological effects of bromantane]”. Voenno-Meditsinskii Zhurnal. 321 (8): 61–65, 96. ISSN 0026-9050.
- ↑ Jump up to:5.0 5.1 Oliynyk, S., Oh, S.-K. (30 September 2012). “The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance”. Biomolecules and Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. ISSN 1976-9148.
- ↑ Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V., Gaĭnetdinov, R. R. (August 1995). “[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]”. Eksperimental’naia I Klinicheskaia Farmakologiia. 58 (4): 8–11. ISSN 0869-2092.
- ↑ Morozov, I. S., Pukhova, G. S., Avdulov, N. A., Sergeeva, S. A., Spasov, A. A., Iezhitsa, I. N. (February 1999). “[The mechanisms of the neurotropic action of bromantan]”. Eksperimental’naia I Klinicheskaia Farmakologiia. 62 (1): 11–14. ISSN 0869-2092.
- ↑ Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., Morozov, I. S. (April 2002). “Toxic effect of single treatment with bromantane on neurological status of experimental animals”. Bulletin of Experimental Biology and Medicine. 133 (4): 380–383. doi:10.1023/a:1016206306875. ISSN 0007-4888.
- ↑ Morozov, I. S., Klimova, N. V., Karpova, T. D., Shestopalov, S. S. (April 1999). “[The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]”. Eksperimental’naia I Klinicheskaia Farmakologiia. 62 (2): 3–6. ISSN 0869-2092.
- ↑ Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS (2000). “[Effect of bromantane on the rat neurologic status in two month course]”. Eksp Klin Farmakol (in Russian). 63 (5): 13–7. PMID 11109517.
- ↑ Vakhitova, I. V., Iamidanov, R. S., Vakhitov, V. A., Seredenin, S. B. (April 2005). “[DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound]”. Molekuliarnaia Biologiia. 39 (2): 276–285. ISSN 0026-8984.
- ↑ “Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz – BtMG)” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
- ↑ “Neue-psychoaktive-Stoffe-Gesetz (NpSG)” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
- ↑ “§ 2 AMG” (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
- ↑ Prof. Dr. Helmut Pollähne (July 11, 2014). “Cannabinoide Kräutermischungen vor dem EuGH: Legal Highs bleiben legal” [Cannabinoid herbal mixtures at the ECJ: Legal highs stay legal] (in German). LTO. Retrieved December 28, 2019.
- ↑ “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
Link to above reference